Barinthus Biotherapeutics Management
Management criteria checks 3/4
Barinthus Biotherapeutics' CEO is Bill Enright, appointed in Aug 2019, has a tenure of 4.75 years. total yearly compensation is $1.81M, comprised of 33.7% salary and 66.3% bonuses, including company stock and options. directly owns 6.39% of the company’s shares, worth $5.10M. The average tenure of the management team and the board of directors is 3.2 years and 4.5 years respectively.
Key information
Bill Enright
Chief executive officer
US$1.8m
Total compensation
CEO salary percentage | 33.7% |
CEO tenure | 4.8yrs |
CEO ownership | 6.4% |
Management average tenure | 3.2yrs |
Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$2m | US$610k | -US$73m |
Sep 30 2023 | n/a | n/a | -US$77m |
Jun 30 2023 | n/a | n/a | -US$55m |
Mar 31 2023 | n/a | n/a | -US$15m |
Dec 31 2022 | US$2m | US$569k | US$5m |
Sep 30 2022 | n/a | n/a | US$11m |
Jun 30 2022 | n/a | n/a | -US$1m |
Mar 31 2022 | n/a | n/a | -US$33m |
Dec 31 2021 | US$3m | US$474k | -US$51m |
Sep 30 2021 | n/a | n/a | -US$46m |
Jun 30 2021 | n/a | n/a | -US$41m |
Mar 31 2021 | n/a | n/a | -US$29m |
Dec 31 2020 | US$3m | US$350k | -US$18m |
Dec 31 2019 | US$381k | US$128k | -US$21m |
Compensation vs Market: Bill's total compensation ($USD1.81M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
CEO
Bill Enright (61 yo)
4.8yrs
Tenure
US$1,811,611
Compensation
Mr. William J. Enright, also known as Bill, MBA, is an Independent Director of Bullfrog AI Holdings, Inc. from February 14, 2023. He serves as Chief Executive Officer & Director of Barinthus Biotherapeutic...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 4.8yrs | US$1.81m | 6.39% $ 5.1m | |
Chief Scientific Officer | 1.3yrs | US$1.71m | 0% $ 0 | |
Chief Business Officer | 6.6yrs | US$731.06k | 0.27% $ 213.6k | |
Co-Founder | no data | US$48.98k | no data | |
Co-Founder & Scientific Advisor | no data | US$61.61k | no data | |
CFO & Company Secretary | 1.7yrs | no data | no data | |
Head of Clinical Operations | no data | no data | no data | |
Head of IP | no data | no data | no data | |
Senior Vice President of Synthetic Immunotherapies | no data | no data | no data |
3.2yrs
Average Tenure
43.5yo
Average Age
Experienced Management: BRNS's management team is considered experienced (3.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 4.8yrs | US$1.81m | 6.39% $ 5.1m | |
Independent Non-Executive Director | 3.3yrs | US$81.69k | 0.0044% $ 3.5k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 3.3yrs | US$81.06k | 0.0077% $ 6.2k | |
Independent Chairman of the Board | 5.8yrs | US$117.13k | 0.12% $ 98.9k | |
Independent Non-Executive Director | 6.3yrs | US$85.42k | 0.027% $ 21.5k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Non-Executive Director | 4.3yrs | US$71.11k | 0.0077% $ 6.2k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data |
4.5yrs
Average Tenure
60.5yo
Average Age
Experienced Board: BRNS's board of directors are considered experienced (4.5 years average tenure).